Press Releases


DETECT program studies validate clinical relevance of CTC HER2 phenotypes in metastatic breast cancer patients with HER2 negative primary tumor

Results presented at the 2020 San Antonio Breast Cancer Symposium confirm the relevance of screening for HER2+ CTCs from blood samples in patients with a HER2 negative primary tumor biopsy to optimize treatment strategy and patient outcome

continue →

Topics: CELLSEARCH, metastatic breast cancer, HER2, San Antonio Breast Cancer Symposium, CTC phenotyping